However, the trial results do raise some important questions regarding the durability of Nuplazid’s benefit and the likelihood of a phase 3 success. Can Nuplazid deliver an important win for Acadia in this tough-to-treat disease? In this clip from The Motley Fool’s Industry Focus: Healthcare podcast, analyst Kristine Harjes is joined by contributor Todd Campbell to discuss the trial results and highlight what should be on investors’ minds as Acadia Pharmaceuticals preps for phase 3 studies.